Initial Data from APEX Phase 2 Study of Bezuclastinib in Advanced Systemic Mastocytosis Investor Webcast Presented at the European Hematology Association Congress June 10, 2022 Forward Looking Statement and Risk Factors This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 Par Value COGT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38443 COGENT BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 46-5308248 (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, $0.001 Par Value COGT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-------------------------------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, $0.001 Par Value COGT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, $0.001 Par Value COGT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------------------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38443 COGENT BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 46-5308248 (State or other jurisdicti ...

Developing Precision therapies for genetically defined diseases Corporate Presentation Q1 2021 | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 Par Value COGT The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi ...

Acquisition and Collaborations - The company completed the acquisition of Kiq Bio LLC on July 6, 2020, focusing on developing novel therapies for cancer patients[60]. - Collaboration revenue for Q2 2020 was $0.5 million, down from $3.1 million in Q2 2019, a decrease of $2.6 million due to the termination of the Collaboration Agreement with Seattle Genetics[77]. - Collaboration revenue for the six months ended June 30, 2020, was $7.6 million, an increase of 22% from $6.2 million in the same period of 2019[84]. Financial Performance - The company incurred a net loss of $13.5 million for the six months ended June 30, 2020, with an accumulated deficit of $137.4 million[64]. - Net loss for Q2 2020 was $7.4 million, an improvement of $3.1 million compared to a net loss of $10.5 million in Q2 2019[76]. - Net loss for the six months ended June 30, 2020, was $13.5 million, an improvement of 39% compared to a net loss of $22.2 million in the same period of 2019[82]. Cash and Funding - As of June 30, 2020, the company had cash and cash equivalents of $21.3 million, expected to fund operations beyond 2022[64]. - The company completed a private placement of 118,638 Series A Preferred Stock for gross proceeds of $104.4 million on July 9, 2020[89]. - The company anticipates significant increases in expenses and capital requirements due to ongoing clinical trials and product development efforts[64]. - The company may need to finance operations through equity offerings, debt financings, collaborations, and licensing arrangements, which could dilute ownership interests[97]. Operating Expenses - Total operating expenses decreased to $7.9 million in Q2 2020 from $13.7 million in Q2 2019, a reduction of $5.7 million[76]. - Total operating expenses decreased to $21.1 million for the six months ended June 30, 2020, down 26% from $28.6 million in the same period of 2019[82]. - Research and development expenses fell to $5.1 million in Q2 2020, down from $10.6 million in Q2 2019, a decrease of $5.5 million primarily due to reduced clinical activity[79]. - Research and development expenses decreased to $14.6 million for the six months ended June 30, 2020, a reduction of 36% from $23.0 million in the same period of 2019[85]. - General and administrative expenses decreased to $2.8 million in Q2 2020 from $3.1 million in Q2 2019, a reduction of $0.3 million attributed to lower professional fees[80]. - General and administrative expenses increased to $6.5 million for the six months ended June 30, 2020, up from $5.6 million in the same period of 2019[86]. Clinical Trials and Development - PLX9486, a clinical-stage KIT D816V inhibitor, has been administered to over 50 advanced solid tumor and GIST patients, showing a median progression-free survival of 11 months[60]. - The overall response rate for PLX9486 in combination with sunitinib was 16.6%, with two partial responses and one complete response observed[60]. - The company plans to initiate additional clinical studies for PLX9486 in GIST patients in the second half of 2021 and in systemic mastocytosis patients in 2021[60]. - All ACTR clinical trials are closed to further enrollment, with closeout activities expected to be completed by the end of Q3 2020[62]. - The company anticipates an increase in expenses related to ongoing activities, particularly in advancing preclinical activities and clinical trials[97]. Accounting and Financial Reporting - The company has critical accounting policies involving revenue recognition of collaboration agreements, accrued research and development expenses, and stock-based compensation[98]. - There are no off-balance sheet arrangements currently in place for the company[99]. - The company has opted out of the extended transition period for compliance with new accounting standards applicable to public companies[101]. - The company’s financial statements do not include adjustments that might result from uncertainties regarding future capital raises or cost-saving measures[97]. Other Financial Metrics - Interest income for Q2 2020 was $0.1 million, consistent with Q2 2019, reflecting lower invested balances[81]. - Interest income decreased to $50,000 for the six months ended June 30, 2020, down from $175,000 in the same period of 2019[88]. - Personnel-related costs in unallocated expenses decreased by $1.9 million in Q2 2020 due to a reduction in headcount[79]. - Operating activities used $16.2 million of cash during the six months ended June 30, 2020, compared to $22.9 million in the same period of 2019[91]. - The company has not generated any revenue from product sales since its inception in 2014[62]. - As of December 31, 2019, the company had U.S. federal and state net operating loss carryforwards of $109.8 million and $110.8 million, respectively[75].